Ultrasound-based radiomics-clinical nomogram for noninvasive prediction of residual cancer burden grading in breast cancer
- PMID: 38538081
- DOI: 10.1002/jcu.23666
Ultrasound-based radiomics-clinical nomogram for noninvasive prediction of residual cancer burden grading in breast cancer
Abstract
Purpose: To assess the predictive value of an ultrasound-based radiomics-clinical nomogram for grading residual cancer burden (RCB) in breast cancer patients.
Methods: This retrospective study of breast cancer patients who underwent neoadjuvant therapy (NAC) and ultrasound scanning between November 2020 and July 2023. First, a radiomics model was established based on ultrasound images. Subsequently, multivariate LR (logistic regression) analysis incorporating both radiomic scores and clinical factors was performed to construct a nomogram. Finally, Receiver operating characteristics (ROC) curve analysis and decision curve analysis (DCA) were employed to evaluate and validate the diagnostic accuracy and effectiveness of the nomogram.
Results: A total of 1122 patients were included in this study. Among them, 427 patients exhibited a favorable response to NAC chemotherapy, while 695 patients demonstrated a poor response to NAC therapy. The radiomics model achieved an AUC value of 0.84 in the training cohort and 0.83 in the validation cohort. The ultrasound-based radiomics-clinical nomogram achieved an AUC value of 0.90 in the training cohort and 0.91 in the validation cohort.
Conclusions: Ultrasound-based radiomics-clinical nomogram can accurately predict the effectiveness of NAC therapy by predicting RCB grading in breast cancer patients.
Keywords: NAC; RCB; breast cancer; radiomics; ultrasound.
© 2024 Wiley Periodicals LLC.
Similar articles
-
Habitat-Based Radiomics for Revealing Tumor Heterogeneity and Predicting Residual Cancer Burden Classification in Breast Cancer.Clin Breast Cancer. 2025 Jul;25(5):444-454. doi: 10.1016/j.clbc.2025.01.014. Epub 2025 Feb 4. Clin Breast Cancer. 2025. PMID: 40000353
-
Improving Prediction Accuracy of Residual Axillary Lymph Node Metastases in Node-Positive Triple-Negative Breast Cancer: A Radiomics Analysis of Ultrasound-Guided Clip Locations Using the SHAP Method.Acad Radiol. 2025 Apr;32(4):1827-1837. doi: 10.1016/j.acra.2024.10.039. Epub 2024 Nov 9. Acad Radiol. 2025. PMID: 39523140
-
Development of a Nomogram-Integrated Model Incorporating Intra-tumoral and Peri-tumoral Ultrasound Radiomics Alongside Clinical Parameters for the Prediction of Histological Grading in Invasive Breast Cancer.Ultrasound Med Biol. 2025 Feb;51(2):262-272. doi: 10.1016/j.ultrasmedbio.2024.09.025. Epub 2024 Oct 29. Ultrasound Med Biol. 2025. PMID: 39477745
-
Evaluation of Multiparametric MRI Radiomics-Based Nomogram in Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Two-Center study.Clin Breast Cancer. 2023 Aug;23(6):e331-e344. doi: 10.1016/j.clbc.2023.05.010. Epub 2023 May 27. Clin Breast Cancer. 2023. PMID: 37321954
-
Progress in research on ultrasound radiomics for predicting the prognosis of breast cancer.Cancer Innov. 2023 Jul 11;2(4):283-289. doi: 10.1002/cai2.85. eCollection 2023 Aug. Cancer Innov. 2023. PMID: 38089749 Free PMC article. Review.
Cited by
-
An XGBoost Machine Learning Based Model for Predicting Ki-67 Value ≥ 15% in T2NXM0 Stage Primary Breast Cancer Receiving Neoadjuvant Chemotherapy Using Clinical Data and Delta-Radiomic Features on Ultrasound Images and Overall Survival Analysis: A 5-Year Postoperative Follow-Up Study.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241265989. doi: 10.1177/15330338241265989. Technol Cancer Res Treat. 2024. PMID: 39051517 Free PMC article.
-
Intratumoral and peritumoral ultrasound radiomics analysis for predicting HER2-low expression in HER2-negative breast cancer patients: a retrospective analysis of dual-central study.Discov Oncol. 2025 Jun 5;16(1):1007. doi: 10.1007/s12672-025-02752-4. Discov Oncol. 2025. PMID: 40471472 Free PMC article.
References
REFERENCES
-
- Li Q, Liu H, Jin Y, et al. Analysis of a new therapeutic target and construction of a prognostic model for breast cancer based on ferroptosis genes. Comput Biol Med. 2023;10:107370.
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;5:209‐249.
-
- Shi Z, Huang X, Cheng Z, et al. MRI‐based quantification of Intratumoral heterogeneity for predicting treatment response to neoadjuvant chemotherapy in breast cancer. Radiology. 2023;7:e222830.
-
- Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;5:1485‐1505.
-
- Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long‐term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;7:164‐172.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical